1. Home
  2. CLLS vs EQ Comparison

CLLS vs EQ Comparison

Compare CLLS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

SELL

Current Price

$0.97

Market Cap

103.8M

Sector

Health Care

ML Signal

SELL

Logo Equillium Inc.

EQ

Equillium Inc.

SELL

Current Price

$1.08

Market Cap

89.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CLLS
EQ
Founded
1999
2017
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.8M
89.4M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
CLLS
EQ
Price
$0.97
$1.08
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$4.45
★ $8.56
AVG Volume (30 Days)
55.6K
★ 299.9K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$1.04
52 Week High
$5.45
$6.20

Technical Indicators

Market Signals
Indicator
CLLS
EQ
Relative Strength Index (RSI) 37.12 33.53
Support Level N/A N/A
Resistance Level $1.28 $1.54
Average True Range (ATR) 0.12 0.13
MACD 0.00 -0.02
Stochastic Oscillator 0.00 6.09

Price Performance

Historical Comparison
CLLS
EQ

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: